Transposable elements are natural, non-viral gene delivery vehicles capable of mediating stable genomic integration. The Sleeping Beauty (SB) transposon has the ability to cut-and-paste the 'gene of interest' into the genome, providing the basis for long-term, permanent transgene expression in transgenic cells and organisms. The SB transposon system is relatively well characterized, and has been extensively engineered for efficient gene delivery and gene discovery purposes in a wide range of vertebrates, including humans. The SB system is a safe and simple-to-use vector that enables cost-effective, rapid preparation of therapeutic doses of cell products. Recently, there has been a growing interest in using the SB system for therapy as evidenced by the large number of pre-clinical studies. SB moved swiftly from pre-clinical to clinical trials in almost a decade. In this article, we highlight the advancements and challenges associated with the SB system in various therapeutic applications. We also provide an overview that has been exploited by spin-off companies based on the SB system.
The high expectation on gene therapy continues to grow, as it holds the potential to provide a cure for myriad genetic diseases by substituting a corrupted gene with the respective functional one to achieve a therapeutic effect. The success of gene therapy is mainly dependent on the safety, efficacy, simplicity, cost-effectiveness and scalability of the vector system used for delivering and expressing the therapeutic gene of interest (GOI) into the cells. The numerous gene delivery approaches can be broadly classified as viral and non-viral mediated (Figure 1 ). Viral vectors have been exploited for clinical use based on their inherent gene delivery capabilities in multiple cell types. In fact, the majority of the gene therapy clinical trials currently use viral vectors. Currently, there are around 600 and 800 gene therapy clinical trials involving retro/lentiviral and AV/AAV vectors, respectively [1]; however, despite their superb delivery capacity, viral vectors do have certain limitations. Whilst AV and AAV vectors are excellent delivery/expression vectors in non-dividing cells, they are diluted out by cell division. To achieve long-term therapeutic effect in dividing cells, multiple doses of administration are required, which induces adverse immune responses [2, 3] . AAVs are also limited by their relatively low packaging capacity (<5 kb). By contrast, both retroviral and lentiviral vectors have the Gene therapy involves delivery of the gene of interest into therapeutically relevant cells. The delivery can be accomplished by several gene delivery systems as summarized in the graphic. Viruses possess the inherent ability to infect and deliver DNA into a wide variety of cell types. This phenomenon has been exploited for various gene therapy applications. Based on the integration ability viral vectors can be further classified into integrating and non-integrating vectors. Non-integrating viral vectors include vectors from adeno-associated virus (AAV), adenovirus (AV), herpes simplex virus 1 amplicon (HSV-1) and baculovirus (Baculo); while integrating viral vectors are derived from lentivirus and retrovirus. Because of the associated disadvantages with viral vectors, recently non-viral vectors have gained significance as an alternative delivery method. Naked DNA can be delivered either by transfection or nucleofection or can be complexed with liposomes and nanoparticles. However, these methods have a limitation of mediating the transient effect, due to the lack of stable genome integration. However, natural gene delivery vehicles like Sleeping Beauty and PiggyBac transposons can overcome the problem of transient expression. Transposons have the inherent ability to stably integrate the gene of interest into the genome, providing long term or possibly permanent therapeutic effect. Sleeping Beauty transposon system has been combined with both nonviral and viral delivery techniques (orange dotted line).
capacity to mediate stable integration of the GOI, resulting in stable expression of the therapeutic gene. While lentiviruses have the capacity to infect both non-dividing and dividing cells, retroviruses such as the Moloney murine leukemia virus (MoLV) are restricted to dividing cells [4] . MoLV prefers to integrate into transcription start sites, whereas lentiviral vectors based on HIV exhibit bias towards integration into active genes [5] . Due to their biased integration pattern, retroand lenti-viral vectors are associated with an elevated risk of both insertional mutagenesis and transactivation of oncogenes around the integration site [6, 7] . Finally, viral production methods are complex, and generally involve high costs, partially associated with regulatory issues.
In contrast to viral vectors, non-viral vectors have been considered for their simplicity, safety and ease of production. Non-viral approaches include physical or chemical delivery methods such as transfection, electroporation/ nucleofection, gene gun and nanodelivery. The bottleneck problems of classical non-viral delivery are its low efficacy and transient nature. However, there are currently over 400 non-viral gene therapy clinical trials [1].
Mobile genetic elements (transposons) are natural gene delivery vehicles capable of genomic insertion. DNA transposons have the ability to transpose within the genome by a cut-and-paste process; however, this process can be restricted to a single excision event from a transfected plasmid to the genome. Stable genomic integration provides the basis for permanent transgene expression in transgenic cells and organisms, thereby addressing the bottleneck problem of classical non-viral delivery. Sleeping Beauty (SB) is a resurrected, synthetic transposon, belonging to the Tc1/mariner family of transposons that is active in a wide variety of vertebrates, including human cells [8, 9] . The potential of the SB-based non-viral integrating system as an alternative to viral vectors has been thoroughly investigated in the last two decades. The studies demonstrated its ability to mediate long-term gene expression in various human cell types, and revealed several advantageous safety features. Currently, the SB transposon vector is the most widely used alternative gene carrier to integrating viral vectors.
THE SB TRANSPOSON SYSTEM
Generally a transposon system includes a transposon and a transposase. The transposon acts as a carrier, which carries the gene to be inserted into the genome. The transposase is the workhorse catalyzing the process of transposition. Naturally, the transposase is located between the inverted terminal repeats (ITRs) of the transposon. Importantly, however, the transposase gene can be replaced with any GOI, and the transposase can govern transposition events when encoded by a separate plasmid in trans. Physical separation of the transposon from the transposase enabled optimization of transposon versus transposase ratio, and also provided the freedom of supplying the transposase in the form of mRNA, instead of DNA [10] . Both components of the SB system, the transposon and the transposase, have been extensively engineered to improve transpositional activity.
Engineering the SB transposon
SB represents the first functionally active DNA transposon in vertebrates [8] . SB was engineered from ancient Tc1/mariner transposon fossils found within the Salmonid genomes by in vitro evolution [8] . The ITRs (230 bp) contains imperfect direct repeats (DRs) of 32 bp in length that serve as recognition signals for the transposase. Binding affinity and spacing between the DR elements within ITR has been crucial for efficient transpositional activities, suggesting that a constrained geometry is required during the pre-integration complex assembly [11, 12] . Optimizing nucleotide residues (including mutations, deletions and additions) within the ITRs of the original SB transposon (pT) resulted in improved transposon versions, such as pT2, pT3, pT2B and pT4 (Table 1 ). For convenience of use, a whole series of transposon vectors with different reporter and selection markers are available [13] .
Engineering the SB transposase
The SB transposase is a 39 kDa protein that possess DNA binding domains, a nuclear localization signal (NLS) and the catalytic domain, featured by a conserved amino acid motif (DDE). Various screens mutagenizing the primary amino acid sequence of the SB transposase resulted in hyperactive transposase versions (Table 2 ). SB100X is 100fold hyperactive compared to the originally resurrected transposase (SB10) in certain cell types [13, 14] .
Mechanism of transposition
Transposition is a relatively well-characterized process, divided into excision and integration steps ( Figure 2) . First, the transposase recognizes the transposon, and binds the ITRs. During synaptic complex formation, the transposon ends are brought together by transposase monomers (presumably forming a tetramer) [15] . The transposase generates a DNA double-strand break upon excision [16] , while single-stranded gaps at the integration site. The pre-integration complex containing the transposon bound transposase performs the integration into the host genome. SB transposition is a highly coordinated reaction that efficiently filters out abnormal, toxic transposition intermediates [12, 17] . Excision leaves a footprint (3 bp) at the donor site. Integration occurs into TA dinucleotides of the genome, and results in target site duplications, generated by the host repair machinery [16, 18, 19] . Overall, SB appears to possess a nearly unbiased, close-to-random integration profile [20] . Transposon integration can be artificially targeted (~10%) to a predetermined genomic locus [20] [21] [22] [23] [24] .
Several host factors of SB transposition, including HMGXB4, HMGB1, BANF1, KU70 and MIZ-1 have been identified [16, 17, [25] [26] [27] . These factors physically interact with the SB transposase, and assist in different steps of the transposition reaction. In addition to host encoded cellular factors, certain conditions (e.g., serum starvation, DNA methylation) are reported to affect SB transposition [27, 28] .
f SB11 (3-fold higher than SB10) [109] SB12 (4-fold higher than SB10) [66] HSB1-HSB5 (up to 10-fold higher than SB10) [108] HSB13-HSB17 (HSB17 is 17-fold higher than SB10) [111] SB100X (100-fold higher than SB10) [14] SB150X (130-fold higher than SB10) [ 
CURRENT APPLICATIONS OF SB TRANSPOSON TECHNOLOGY
The SB transposon system has been used for diverse genetic applications in vertebrate species, which can be broadly classified as f FIGURE 3
Applications of Sleeping Beauty transposon technology.
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Human clinical trials
The SB transposon system has been successfully used for gene delivery (gene of interest) into a variety of animal models and cell types, including stem cells and primary cells (both in vitro and in vivo). It has been extensively exploited as a mutagenic tool for gene discovery applications. The approach of a forward genetic screen for modeling different cancers in animal models led to the discovery of numerous novel genes associated with cancer (functional oncogenomics). It has been used also a valuable tool in germline transgenesis in various animal species (generating transgenic animals). The SB gene delivery technology has been thoroughly used in several pre-clinical studies to model wide range of metabolic disorders, degenerative diseases and cancers. In addition, the SB system has also been utilized for mapping chromatin landscape, epigenome and 3D genome organization. Currently it is being evaluated in clinical trials as a non-viral gene delivery vector for various gene therapy applications like cancer immunotherapy, Alzheimer's disease and age-related macular degeneration (AMD), all of which involves ex vivo modification of patient cells. The chart represents the distribution of various therapeutic applications of SB system that are categorized based on the approximate number of original research articles published as of March, 2017.
gene delivery and discovery (Figure 3 ) [38] . Briefly, the SB system has been used to generate stable transgenic cell clones in tissue culture [39] (reviewed in [40] ). SB has been also highly valuable in generating transgenic animals, including fish, frog, rat, mouse, rabbit, pig, cow and sea squirt (for a recent review see [41] ). Importantly, the SB-based transgenic technology is able to address previous problems of transgenesis, such as low efficacy, mosaicism, unstable gene expression [42] , and offers novel ways for genetic engineering of even large animals [43] . SB was successfully employed in reprogramming somatic cells into induced pluripotent stem cells (iPSCs) that can be expanded and differentiated into different cell types [44] [45] [46] [47] . The SB-based protocol has also been used for the production of iPSCs in various animal models [ 
TAILORING THE SB TRANSPOSON TECHNOLOGY FOR CLINICAL APPLICATIONS
Here we provide an update on the cell and gene therapy applications. In the last decade, SB-based delivery vectors have been extensively used in pre-clinical animal models (for reviews see [38, [60] [61] [62] [63] ). The encouraging pre-clinical results fueled its promotion towards clinical trials, and currently the technology is being evaluated to treat human diseases including cancer (lymphoma) (Figure 4 ), Alzheimer's disease (AD) ( Figure 5 ) and age-related macular degeneration (AMD) ( Figure 6 ). The preliminary results support further clinical development of SB-based gene therapy approach.
The hyperactive SB transposon system
The latest optimized version of the SB system comprises of the hyperactive SB100X transposase and the pT4 transposon [12, 14] . The SB100X, generated by molecular evolutionary strategy performs with significantly higher efficiency of genomic integration that in certain cells is even comparable to viral performances [14] . Since SB100X can integrate the therapeutic gene more efficiently, relatively lower amounts of DNA are required to achieve similar results compared to the less hyperactive versions [64] . Importantly, protocols optimized for non-hyperactive transposase versions need to be re-optimized to avoid unnecessarily high number of integrated copies of the therapeutic gene.
The hyperactive transposon version, pT4 has optimized substrate recognition [12] . DOI: 10.18609/cgti.2017.014
Switch from DNA to mRNA as a source of transposase
Electroporation/nucleofection of plasmid DNA can be highly toxic to certain cells, including primary stem cells [64] . By contrast, nucleofection of RNA is not significantly more toxic than the nucleofection alone, indicating that the toxicity is not caused by nucleofecting nucleic acid per se. Thus, switching the transposase source from plasmid DNA to mRNA could mitigate the toxicity of the delivery. Furthermore, supplying
Clinical application of Sleeping Beauty transposon technology for cancer immunotherapy.
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Sleeping Beauty system has been successfully used in the clinical trials for engineering T cells to express chimeric antigen receptor (CAR) for use against leukemias and lymphomas. SB-modified T cells were used for autologous or allogeneic hematopoietic stem-cell transplantation (HSCT). Shown here is a schematic depicting the autologous cancer immunotherapy involving engineering patient's own cells to recognize antigens presented by cancer cells and destroy them. The illustration shows chimeric antigen receptor (CAR)-T-cellbased adoptive immunotherapy for hematological malignancy. Peripheral blood CD4 + T cells isolated from the patient's blood that are genetically modified using the SB system. The engineered cells express relevant cell surface CAR that can recognize the surface antigens of malignant cells. To generate sufficient number of engineered cells for clinical application the CAR-modified T-cells are subjected to ex vivo expansion, and then infused back into the respective patient where tumor cells are recognized and killed by CAR + T-cells.
the transposase as mRNA would ensure its transient expression, and decrease the risk of remobilization of the integrated therapeutic gene (safety concern) [10].
Extending the cloning capacity of the SB-based vector: the SA transposon
The transposition efficiency of SB is inversely correlated with the actual size of the transposon over 7.5 kb [9] . The 'sandwich' (SA) configuration of the transposon was aimed to improve the mobilization of larger cargos. The SA transposon consists of four ITRs in total, with two complete elements flanking the GOI in an inverted orientation (Figure 7) . Such an arrangement of a Tc1-like transposon was observed to mobilize large (>10kb) pieces of genomic DNA in f FIGURE 5 
Regenerate dying cholinergic neurons Degeneration
Illustration of ECB device for AD: Human retinal pigment epithelial cells (ARPE-19) are genetically engineered using the Sleeping Beauty system to express nerve growth factor (NGF). Engineered cells are encapsulated into an implant (semi-permeable hollow fiber membrane that allows the influx of nutrients and the efflux of NGF) providing an internal cell-supportive scaffold matrix for cell adherence and survival. The implant was validated by placing them in sterile containers filled with serum-free medium at 37 °C for up to 4.5 weeks. The validated implants are surgically implanted into the basal forebrain of AD patients. The cells are protected from immune rejection by the semipermeable membrane, and thus no immunosuppression is required during the treatment. The implanted ECB device secretes NGF that can arrest and might reverse the degeneration of the basal forebrain cholinergic neurons (as shown in the adjoining inlet at the bottom).
f FIGURE 6
Gene therapy approach utilizing Sleeping Beauty transposon technology for the treatment of exudative age-related macular degeneration (AMD 
Delivery of the SB transposon system
Several non-viral gene delivery strategies have been tested for delivering SB constructs in vitro. In hard-to transfect cell types electroporation/ nucleofection appears to be the most effective. A current limitation of this strategy for clinical applications is its capacity to engineer low number of cells. In principle, a flow through electroporation strategy could be beneficial to increase the number of engineered cells. Besides nucleofection, nanoparticle-like carriers proved to be efficient to deliver the SB system. Notably, these carriers are also suitable to be combined with various targeting molecules that allow cell type specific transfer. In one example, hard-to-transfect mesenchymal stem cells (MSCs) could be targeted with high efficacy (∼52%) by using engineered lipid-based nanoparticles (LBNs) encapsulating the SB system. These LBNs are chemically modulated to present synthetically reiterated MSC-targeting peptides on their surface [69] . Nanoparticle-like protocells with SB encapsulated inside can deliver the therapeutic gene into cancer cells, when folic acid is incorporated as a cancer cell-targeting motif [70] . Furthermore, special hepatocyte-targeted carriers, such as proteoliposomes containing galactose-terminated glycoproteins (e.g., the F protein of the Sendai virus) were demonstrated to effectively deliver the SB cargo into hepatocytes [71] . In a different approach, cell type-specific gene targeting using hyaluronanand asialoorosomucoid-coated nanocapsules harboring the SB system were successfully used in vivo to direct genes to liver sinusoidal endothelial cells and hepatocytes, respectively [72] . Collectively, these studies imply that with the targeting ligand modification, the nanoparticle-like carriers can be developed as efficient gene delivery and targeting gene vehicles, highlighting their therapeutic potential.
Apart from the non-viral strategies, various SB-based viral hybrid technologies have been developed that can advantageously merge the excellent delivery properties of the viral vectors and the superior safety properties of the SB ( Figure 8 ) (also reviewed in [41, 63] ). Currently, one of the most promising strategies is the in vivo gene transduction system based on a hybrid transposon/adenovirus vector [73] and hyperactive SB transposase (SB100X) [74] . This in vivo strategy is effective and safe, and performs without the requirement of ex vivo expansion and transduction of hematopoietic stem cells (HSCs) [75] .
Eliminating bacterial sequences from the transposon vector
Non-viral delivery of large plasmid DNA molecules via electroporation is highly toxic to certain cell types, f The SB transposon system can be delivered (large rounded rectangle) into the cells by combining with any nucleic acid-delivery techniques like transfection (using the commercial transfection reagents) or nucleofection (electro-transfer of nucleic acids directly into the nucleus) or by complexing with liposomes (nucleic acids are packed directed into the liposomes) or by complexing with nanoparticles (liposome protamine/DNA lipoplex with targeting peptides) or by hybrid viral vectors (nucleic acids are packaged into virions). Once inside the cell, they can traverse the nuclear membrane (oval inside the cell) by a poorly understood process. Here delivery of the SB system via nucleofection is illustrated in the graphic. Transcription of the SB transposase gene results in an mRNA, which is translated into a protein in the cytoplasm. Note that the SB transposase can also be supplied in the form of an mRNA (as shown by the white dotted arrows) directly into the nucleus via nucleofection instead of plasmids. Using mRNA instead of DNA is beneficial in preventing genomic integration of the transposase gene and in reducing toxicity upon electrotransfer. The transposase protein then binds to the transposon ends (ITRs) resulting in excision and ultimately integrating into the chromosomal DNA of the genome. Stable genomic integration confers long-term expression of the gene of interest delivered by the transposon.
including primary T cells. Reducing the size of the DNA, and using supercoil DNA proved to be advantageous modifications in the delivery protocol [76, 77] . Furthermore, the use of conventional plasmids as vectors that are propagated and isolated from bacteria raises a safety concern and a roadblock for broad clinical applications. In fact, the presence of bacterial backbone sequences on conventional plasmids such as antibiotic resistance gene and bacterial origin of replication has a number of negative consequences (Figure 9i ). First, bacterial sequences are recognized and trigger gene silencing [78, 79] . Second,
Schematic overview of alternative vector selection approaches according to the size and transfection efficiency.
Transfection efficiency and expression
Plasmid size and bacterial backbone expression of antibiotic resistance genes can also induce undesired immune responses [79] . Furthermore, transmission of antibiotic resistance genes to the cells or the microbiota of the patient via horizontal gene transfer generates potential risks. For the above safety considerations regulatory agencies recommend avoiding the use of antibiotic resistance markers.
The need to eliminate redundant bacterial backbone sequences motivated researcher's to consider new approaches that reduces the size and bacterial sequence content of the plasmids. These efforts resulted in the development of plasmid free of antibiotic resistance (pFAR; see below and Figure 9ii) and minicircle (MC) vectors (Figure 9iii ). pFAR vectors are produced under selection pressure in a genetically modified E. coli, which contains an amber mutation in the thymidylate synthase gene. Introduction of pFAR plasmids having the suppressor transfer RNA gene (Sup t-RNA) into the mutant E. coli can restore normal growth, providing a selection pressure for the maintenance of pFAR miniplasmids. The pFAR miniplasmids are much more efficient (in transfection as well as expression in vitro and in vivo) compared to the conventional plasmids (Figure 9ii) [80] . Importantly, the pFAR and SB technologies were successfully combined [Johnen S, In press], and would be used in the clinical trial to treat AMD.
Minicircle DNA vectors represent small and supercoiled molecules that are devoid of any bacterial sequences, and contain almost exclusively the GOI. They are produced by the inclusion of site-specific intramolecular recombination motifs between the GOI and bacterial backbone in the parental plasmid. SB transposon and transposase minicircle constructs have been examined and optimized for safety and efficacy in various cell types [77] , including primary T cells [76] . A minicircles-based SB system has been also used for efficient germline transgenesis [81] . Minicircle vectors seem to improve the transfection efficiency and transgene expression, while decreasing the toxicity associated with DNA delivery (Figure 9iii ).
Collectively, miniplasmid vectors could be optimized for a variety of cell types, might meet future regulatory requirements for gene therapy and vaccine products, and set a new standard in advanced cellular and gene therapy.
Selection strategies for engineered cells expressing the gene of interest
Certain clinical applications require a large number of engineered cells. Thus, high efficacy of delivery and the frequency of therapeutic gene integration are crucial. In addition, it might be necessary to further enrich engineered cell cultures by using selective culturing protocols. Ideally, the selection period should be short. The following selection strategies have been tested for selecting genetically modified cells using the SB system.
In a cancer immunotherapy application, T cells are genetically modified by nucleofecting the SB system to express chimeric antigen receptor (CAR) that redirects specificity towards tumors. For example, CD19-specific CAR + T cells could be selectively expanded on K562-derived artificial presenting cells (aAPC) co-expressing human CD19 and in the presence of an array of co-stimulatory molecules. Co-expression of CD19 serves to specifically propagate the genetically modified T cells, leaving those cells that did not integrate the transposon to die from neglect. This method of expansion strategy can efficiently overcome the toxicity of nucleofection and yield sufficient numbers of CD19-specific CAR + T cells for clinical applications [82, 83] .
In an alternative protocol, administration of irradiated PBMCs was used to overcome cell death following SB-mediated gene transfer of CAR-modified cytokine-induced killer cells (CIKs). This clinical-grade protocol enables both robust gene transfer and efficient T cell expansion [84] .
In addition, the SB transposon system has also been used for multiplexed gene transfer in conjugation with methotrexate selection. The strategy allows stable expression of up to three different transgenes in human CD4 + T cells [85] .
Alternatively to cytotoxic drugs, a chemically responsive amplification mechanism can be used for selecting the engineered cells. A nearly pure population of stably transduced cells can be generated by non-viral delivery of desired transgenes through a combination of SB transposon-mediated integration and selective amplification using a chemically induced dimerizer (CID) [86] . This positive selection strategy is responsive to a small molecule trigger. Using this fast and efficient selection strategy, engineered cell populations with >98% purity could be obtained within 1 week. Dimerizer-induced cell growth could provide cost and reproducibility advantages to natural ligand stimulation in ex vivo cell culture, and could be used to control engineered cell behavior in vivo.
A 'traceless selection system' can efficiently select for engineered cells, and can be also used to select against cells that retain expression of the transposase gene. In this approach, the transposase is expressed together with a tractable fluorescent reporter. The strategy is based on the observation that upon co-transfection of both the transposase and transposon constructs, the presence of the transposase also reports on successful transposition events with high frequency. This concept could be used to produce highly enriched, auxiliary gene-free, cell products [87] that meet important safety requirements.
Regulation of the transgene expression
Transcriptional regulation could control the timing and dose of the expression of the therapeutic gene. In principle, the SB vector, possessing negligible enhancer/promoter activity on its own [26, 88] can be easily adopted for transcriptional regulation. For regulated transgene expression 'all-in-one' TET SB vectors display a relatively low signalto-noise ratio, resulting in regulatory windows of around 25,000-fold [89] . For safety concerns it is desirable to secure even elimination of the therapeutic gene. In conjunction with the SB system, thymidine kinase (TK) can be used for conditional ablation of the therapeutic construct [90] . f A recently reported wholebody non-invasive imaging provides a method to examine long-term bio-distribution and persistence of the engineered cells.
Supporting protocols to monitor the safety and efficacy
In this technology, bioluminescent imaging is used to monitor the signal emitted by firefly luciferase from the SB vector in vivo. The positron emission tomography (PET) is applied following injection of 
Clinical evaluation of SB transposon system/ technology
Assignees for SB patent applications are associated with two leading organizations (University of Minnesota and the Max Delbrück Center for Molecular Medicine (MDC)). As discussed above (Figures 4-6) , SB transposon technology applications span the cell and gene therapy industry market that has experienced rapid growth in the last few years (Table 4 & Figure 10 ). The 'simple' search (with the term 'sleeping beauty transposon') using the patentscope search tool [92] of world intellectual property organization f Percentage share of the International Patent Classification (IPC). Majority of the patents involving the SB has been submitted in the category-C12N (inventions concerning microorganisms, enzymes; compositions thereof mutation or genetic engineering); A61K (inventions concerning pharmaceutical field-preparations for medical purposes); A01K (inventions concerning animal husbandry); A01N; C07H and G01N. Academic-industrial partnership can bridge the 'gap' between research done in academia and its translation into marketable products. Recently, the University of Minnesota's patented SB-based gene delivery technology (SB11 and pT2) pooled with patents of cancer therapies practiced by the University of Texas' MD Anderson Cancer Center. This bi-institutional technology sparked a landmark of $100 million licensing deal with biotech company Intrexon Corp. and pharmaceutical company Ziopharm Oncology [106] . 2 months later, the drugmaker Merck offered to pay Intrexon and Ziopharm nearly $1 billion, plus royalties for an upstart CAR T cancer drug development project [97] . (WIPO) resulted in 19 patent applications or documents, involving SB. Majority of the patent applications are from the USA and Europe. Most of the SB patents are in the category C12N (inventions concerning microorganisms, enzymes; compositions thereof mutation or genetic engineering), followed by A61K (inventions concerning pharmaceutical field-preparations for medical purposes) and A01K (inventions concerning animal husbandry) ( Figure 10A ).
There are currently ten ongoing clinical trials in USA employing SB (Table 5 ). These trials use the SB11/ pT2 version of the transposon system aiming to treat B-cell malignancies and metastatic breast cancer. In addition, the hyperactive SB100X-generated stable cell line in conjunction with Encapsulated Cell Biodelivery TM was trialed to treat AD patients (ClinicalTrials.gov identifier: NCT01163825) ( Table 5 ). Another clinical trial is planned to launch in 2017, which would employ SB100X and pFAR technologies to treat AMD (TargetAMD [93] ).
Because of the significant complexities associated with cell engineering and therapy, partnerships tend to link different players, including academic research institutions and the biotech/pharma industries ( Figure 10B) . In one example, University of Minnesota has combined its patented SB-based gene delivery technology (SB11 and pT2) with intellectual properties of cancer therapies practiced by the University of Texas' MD Anderson Cancer Center. This joint deal was meant to create the first-of-its kind non-viral immunotherapy treatment to support the patient's immune system to fight against cancer. In an attempt to develop and evaluate the potential of immunotherapy to treat solid tumors, Intrexon and Ziopharm announced a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI). This join corporation will use T-cell receptors (TCRs) expressed by the non-viral SB system [94]. Recently, Immusoft acquired an exclusive access to use the SB transposon technology through acquisition of Discovery Genomics, Inc., which will be used for the development of autologous cell therapy products for treating a variety of diseases. Immusoft's proprietary Immune System Programming (ISP™) technology would be used to program patients own B cells to generate miniature drug factories in the body. The Immusoft technology platform would use the SB transposon system for inserting genes encoding the correct human homolog of a missing or defective protein(s) to boost the patient's own immune cells. Certain companies are providing reagents and custom services of SB transposon technology for research and clinical applications (Table 4 ).
In an attempt to replicate the success of SB in therapeutic applications, MDC has established an exclusive licensing agreement and strategic collaboration with For- f 
TRANSLATIONAL INSIGHT
Despite periods of serious stagnation over the past few decades, the future of cell and gene therapy seems to be brighter. The turnaround began about a decade ago, and has been on an exponential trajectory by overcoming the early issues. Besides using traditional viral vectors, recent years have seen major breakthroughs in genome engineering systems, such as transposon-mediated gene delivery and CRISPR/Cas9-mediated genome editing tools. As discussed above, SB appears to be a relative low risk and efficient gene delivery vector, and represents a safer alternative to integrating viral vectors.
In parallel, rapid development occurred also in the CRISPR/Cas9 technology that can be developed for genome editing. These technologies became available in many species and have revolutionized genome engineering. These two approaches appear to have distinct features, and might occupy complementary niches in therapeutic applications. For example, due to its ability to specifically target sequences, the CRISPR/Cas9 system appears to be ideal for knocking out strategies. Currently it is tested in many pre-clinical studies, and could be on its way towards clinical applications in the near future. By contrast, although f FIGURE 11
Milestones and developments in Sleeping Beauty transposon technology for various therapeutic applications as of March 2017.
McClintock was awarded the Nobel Prize for the discovery of transposons Resurrection and establishment of SB transposon system Integration profile of SB was found to be fairly random proof-of-concept studies exist to demonstrate that SB can be targeted to predetermined genomic loci [23, 24] , the current SB system is not suitable for flexible and efficient sequence-specific genome targeting. Nevertheless, among integrating gene delivery vectors the SB system has the highest chance of landing in a genomic safe harbor [35] . On the other side, today's CRISPR/Cas9 strategies to manipulate large genomic regions (knocking in) face clear limitations for clinical translation. The current knock-in protocols are tightly dependent on homologous recombination of the cellular DNA repair machinery that has low activity in many clinically relevant cell types. Thus, compared to CRISPR/Cas9, the SB system is more suitable for applications that require 'gene insertion' (especially large genes). Regarding safety, the SB-mediated transgene integration is highly regulated and precise, and does not generate unspecific double stranded breaks in the genome (off target). In addition to ex vivo applications, an important milestone in the SB technology is in vivo delivery. This gene transduction system is based on a hybrid transposon/ adenovirus vector and the hyperactive SB transposase (SB100X) [74] . This in vivo strategy is effective and safe in hematopoietic stem cells (HSCs), and performs without the requirement of ex vivo expansion and transduction [75, 96] . This system may overcome some of the current difficulties associated with cell collection and manufacturing, and provide technical advances for gene therapy.
Collectively, the significant efforts invested in developing genome-engineering tools begin to pay dividends, as we witness an increasing interest in using them in various applications, including cell and gene therapy. The SB-mediated gene transfer is currently being evaluated in 12 clinical trials ( Figure  11 ). In the coming years, the number of trials using genome-engineering systems is forecasted to increase, attracting further investment from the pharma as well as biotech companies.
